Citadel Advisors
WHWK

Citadel Advisors’s Whitehawk Therapeutics WHWK Stock Holding History

Citadel Advisors’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,100
Closed -$3.74K – 15724
2025
Q1 		$3.74K Sell
2,100
-1,000
-32% -$2.61K ﹤0.01% 13943
2024
Q4 		$9.78K Buy
+3,100
New +$7.02K ﹤0.01% 13628
2024
Q3 		– Sell
-2,500
Closed -$3.65K – 15480
2024
Q2 		$3.65K Buy
2,500
+1,800
+257% +$3.34K ﹤0.01% 13567
2024
Q1 		$1.64K Sell
700
-5,100
-88% -$9.83K ﹤0.01% 14100
2023
Q4 		$11.7K Buy
5,800
+5,000
+625% +$21K ﹤0.01% 13032
2023
Q3 		$3.87K Sell
800
-500
-38% -$2.91K ﹤0.01% 13542
2023
Q2 		$8.89K Sell
1,300
-1,300
-50% -$10.1K ﹤0.01% 13288
2023
Q1 		$18.8K Buy
2,600
+2,400
+1,200% +$25.6K ﹤0.01% 13110
2022
Q4 		$2.57K Buy
+200
New +$2.61K ﹤0.01% 14316

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Citadel Advisors's WHWK Position: Q1 2026 in Review

Citadel Advisors reduced its Whitehawk Therapeutics (WHWK) stake by 7.2% in Q1 2026, selling an estimated $22.2K and leaving 91,852 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #10357.

Citadel Advisors first reported a position in WHWK in Q3 2019 and has held it in 25 quarters since. The position peaked at $5.57M in Q4 2021. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Citadel Advisors held 91,852 shares of Whitehawk Therapeutics worth $317K as of Q1 2026.
  • Citadel Advisors sold 7,098 Whitehawk Therapeutics shares in Q1 2026, an estimated $22.2K.
  • Whitehawk Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10357 holding.
  • Citadel Advisors first reported a position in Whitehawk Therapeutics in Q3 2019 and has held it in 25 quarters since.
  • Citadel Advisors's Whitehawk Therapeutics position peaked at $5.57M in Q4 2021.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.